Virbac Corporation

Hangzhou Solipharma Co., Ltd.

Qilu Regor Therapeutics Inc.

Xiawei Jiang

Wenge Zhong

Wei Guo

Xiaoxia Sheng

Xiaohong Sheng

Britta Olenik

Sylvia Dworacek

Fabian Simons

Zheng Jane Li

Li Zhang

Pengyuan Chen

Anja Förster

Crystalline forms of Compound (A) represented by the following structural formula, and their corresponding pharmaceutical compositions, are disclosed. The crystalline forms are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms are also disclosed. The present disclosure also provides methods of treating or preventing diseases or conditions such as type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease in a subject.

Crystal forms of GLP-1R agonists and uses thereof

The present invention relates to a crystalline modification of Modoflaner 6-fluoro-N-(3-(2-iodo-4-(perfluoropropan-2-yl)-6-(trifluoromethyl)phenylcarbamoyl)-2-fluorophenyl)nicotinamide of formula (I):

Tablet comprising modoflaner as an active component

The present invention relates to the crystalline forms of a 5-HTreceptor agonist 2,4,6-trifluoro-N-[6-[(1-methyl-piperidine-4-yl)carbonyl]pyridin-2-yl]-benzene formamide (lasmiditan) and its hydrochloride. The crystalline forms of the present invention have advantages in crystallinity, hygroscopicity, morphology, crystal form stability, and chemical stability as compared with the known forms of lasmiditan and lasmiditan hydrochloride. The present invention also relates to processes for the preparation of the crystalline forms of lasmiditan and lasmiditan hydrochloride, pharmaceutical compositions thereof and their use in treating and/or preventing a patient's migraine and other diseases or conditions associated with 5-HTreceptor dysfunction.

Crystalline forms of lasmiditan, preparation methods, pharmaceutical compositions and uses thereof

Growing community of inventors

Zhejiang, China

Xiawei Jiang